A commercial-stage immunotherapy company focused on the development of novel treatments for B-cell malignancies and autoimmune diseases.
About
TG Therapeutics is a commercial-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with B-cell malignancies and autoimmune diseases. The company's pipeline includes a combination of novel small molecules and antibodies designed to target key pathways involved in these diseases. Their lead programs, ublituximab and umbralisib, are being investigated in various hematologic cancers and autoimmune conditions.
Tags
Total Employees
497
Current headcount
Performance
Company Timeline
No timeline data for this period
Score Breakdown
50Traction
60Team
60Visibility
2Profile
0Community
15Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does TG Therapeutics do?
TG Therapeutics is a commercial-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with B-cell malignancies and autoimmune diseases. The company's pipeline includes a combination of novel small molecules and antibodies designed to target key pathways involved in these diseases. Their lead programs, ublituximab and umbralisib, are being investigated in various hematologic cancers and autoimmune conditions.
How much funding has TG Therapeutics raised?
TG Therapeutics has raised a total of $360M in funding. The most recent round on record is Public Stock Offering.
Where is TG Therapeutics headquartered?
TG Therapeutics is headquartered in New York, New York, USA.
When was TG Therapeutics founded?
TG Therapeutics was founded in 2011.
What industry does TG Therapeutics operate in?
TG Therapeutics operates in Biotechnology, Pharmaceuticals, Healthcare.
How many employees does TG Therapeutics have?
TG Therapeutics has approximately 497 people on record.
What is TG Therapeutics's current status?
TG Therapeutics's current operating status is: Acquired.